Recombinant zoster vaccine immunization rate in patients on Janus kinase inhibitors for rheumatologic and dermatologic conditions. [PDF]
Michaud JB +6 more
europepmc +1 more source
Factors associated with the effectiveness and safety of Janus kinase inhibitors in rheumatoid arthritis: an 8-year observational study from the JAGUAR Registry. [PDF]
Martinez-Molina C +4 more
europepmc +1 more source
Epidermolysis bullosa pruriginosa: A retrospective cohort study highlighting secondary cutaneous amyloidosis and response to Janus kinase inhibition. [PDF]
Hou PC +6 more
europepmc +1 more source
Janus Kinase inhibitors associated with reduced anterior uveitis risk in autoimmune diseases. [PDF]
Wu SL +13 more
europepmc +1 more source
Refractory nail lichen planus treated successfully with the Janus kinase 1 inhibitor abrocitinib: A case report. [PDF]
Wang L, Lei X, Li L, Cheng Q.
europepmc +1 more source
Updated review of Janus kinase inhibitors for the management of inflammatory bowel disease. [PDF]
Malakar S, Giri S, Jena A, Nath P.
europepmc +1 more source
Peribiliary Inflammatory Phlegmon Masquerading as Cholangiocarcinoma in Janus Kinase 2 V617F-positive Primary Myelofibrosis: A Multimodality Imaging Diagnosis. [PDF]
Khaladkar SM, Vasan PS.
europepmc +1 more source
Janus kinase inhibitor use and incident dry eye disease in rheumatoid arthritis: a real-world cohort study. [PDF]
Lin CC +4 more
europepmc +1 more source
Diversifying the triquinazine scaffold of a Janus kinase inhibitor. [PDF]
Mulliri K +5 more
europepmc +1 more source

